ACHE and early-onset autosomal dominant Alzheimer disease: Molecular docking has been extensively used to identify acetylcholinesterase (AChE) inhibitors and analyze the interaction of previously known compounds, aiming to develop more effective drugs for treating Alzheimer’s disease.